Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

About this update from Liminatus Pharma, Inc.

[{"type":"text","content":"Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovation","length":166,"tagName":"p"},{"type":"text","content":"LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework.","length":386,"tagName":"p"},{"type":"text","content":"This internal review is part of Liminatus’s continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments—including blockchain-based assets—that may enhance treasury efficiency and diversify non-operating capital reserves.","length":390,"tagName":"p"},{"type":"text","content":"“Liminatus remains fully committed to our mission of developing life-changing cancer therapies,” said Chris Kim, CEO of Liminatus Pharma, Inc. “At the same time, we believe responsible treasury management is essential to supporting our long-term goals. This review is not a shift in our business focus, but an effort to evaluate modern financial tools—such as regulated digital assets—that may enhance the way we manage non-operating capital.”","length":443,"tagName":"p"},{"type":"text","content":"Liminatus emphasizes that this is an exploratory process only. As of today, the Company has not entered into any agreements regarding the acquisition, custody, or use of digital assets. Any potential future steps would be subject to approval by the Board of Directors and undertaken in full alignment with U.S. Securities and Exchange Commission (SEC) regulations and public company disclosure standards.","length":404,"tagName":"p"},{"type":"text","content":"About Liminatus Pharma, Inc.","length":28,"tagName":"p"},{"type":"text","content":"Liminatus is a preclinical-stage biopharmaceutical company developing immunotherapies for patients with cancer. The Company is advancing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune...

More updates from Liminatus Pharma, Inc.